Comparing Glyxambi vs Semaglutide
| Glyxambi (empagliflozin / linagliptin) | Semaglutide |
|
|---|
| Glyxambi (empagliflozin / linagliptin) | Semaglutide |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Type 2 Diabetes. Glyxambi may also be used for purposes not listed in this medication guide. |
Prescription only
Semaglutide (Ozempic, Rybelsus) lowers blood sugar levels by mimicking the effects of GLP-1, a naturally occurring hormone that stimulates insulin secretion and lowers glucagon secretion from the... View more |
||||||||
| More about Glyxambi (empagliflozin / linagliptin) | More about Semaglutide | ||||||||
| Ratings & Reviews | |||||||||
|
Glyxambi has an average rating of 6.7 out of 10 from a total of 23 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 26% reported a negative effect. |
Semaglutide has an average rating of 6.9 out of 10 from a total of 2706 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Glyxambi side effects |
View all Semaglutide side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Glyxambi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Ozempic, Rybelsus, Wegovy | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
12.4 hours |
168 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 485 drugs are known to interact with Glyxambi:
|
A total of 274 drugs are known to interact with Semaglutide:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
January 30, 2015 |
December 05, 2017 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Lantus
Lantus is a long acting form of insulin used to treat type 1 or type 2 diabetes. Learn about side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tresiba
Tresiba (insulin degludec) is used to treat diabetes mellitus. Includes Tresiba side effects ...
Levemir
Levemir (insulin detemir) is a long acting insulin used to treat diabetes in adults and children ...
Victoza
Victoza helps control blood sugar levels and reduce the risk of serious heart problems in people ...
Novolog
NovoLog is a fast-acting insulin used to treat diabetes to control blood sugar levels in adults and ...
Basaglar
Basaglar (insulin glargine) is a long-acting insulin that is used to improve blood sugar control in ...
Soliqua
Soliqua 100/33 (insulin glargine and lixisenatide) is used to treat type 2 diabetes. Includes ...
Toujeo SoloStar
Toujeo (insulin glargine) is an injection used to treat type 1 or type 2 diabetes. Includes Toujeo ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.